Author: Ahmad Abuhelwa

Population in vitro-in vivo correlation model linking gastrointestinal transit time, pH with the in vivo disposition kinetics of itraconazole

Ahmad Y. Abuhelwa (1), Stuart Mudge (2), David Hayes (2), Richard N. Upton (1), David J.R. Foster (1)
1. Australian Centre for Pharmacometrics, School of Pharmacy and Medical Sciences, University of South Australia, South Australia, Australia. 2. Mayne Pharma International, South Australia, Australia.

Background Sporanox and SUBA-itraconazole are oral capsule formulations of itraconazole with characteristically different pH-dissolution profiles. Oral administration of itraconazole is associated with marked inter-subject and intra‑subject pharmacokinetic variability due, in part, to variability in the drug’s absorption from the GI tract [1]. Objectives The objectives of this work were to : (1) Establish an in vitro-in […]

Read More

Population pharmacokinetic modelling of itraconazole and hydroxyl-itraconazole for oral Lozanoc® and Sporanox® capsule formulations in healthy volunteers in fed and fasted state.

Ahmad Y. Abuhelwa (1), David J.R. Foster(1), Stuart Mudge (2), Richard N. Upton (1)
1. Australian Centre of Pharmacometrics, School of Pharmacy and Medical Sciences, University of South Australia, SA 5000, Australia, 2. Mayne Pharma International, SA 5106, Australia

Background: Itraconazole is an orally active broad spectrum anti-fungal agent used for treatment of fungal infections. It has a complex absorption kinetics with high between- and within-individual variability in addition to food effects. Hydroxy-itraconazole is the predominant active metabolite. Lozanoc is a novel Mayne Pharma formulation of oral itraconazole with significantly greater bioavailability than the […]

Read More